Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy.
Department of Biology and Biotechnologies "L.Spallanzani", University of Pavia, 27100 Pavia, Italy.
Molecules. 2020 Sep 2;25(17):4014. doi: 10.3390/molecules25174014.
The aim of the present report is to review the literature addressing the methods developed for the purification of alpha1-antitrypsin (AAT) from the 1950s to the present. AAT is a glycoprotein whose main function is to protect tissues from human neutrophil elastase (HNE) and other proteases released by neutrophils during an inflammatory state. The lack of this inhibitor in human serum is responsible for the onset of alpha1-antitrypsin deficiency (AATD), which is a severe genetic disorder that affects lungs in adults and for which there is currently no cure. Being used, under special circumstances, as a medical treatment of AATD in the so-called "replacement" therapy (consisting in the intravenous infusion of the missing protein), AAT is a molecule with a lot of therapeutic importance. For this reason, interest in AAT purification from human plasma or its production in a recombinant version has grown considerably in recent years. This article retraces all technological advances that allowed the manufacturers to move from a few micrograms of partially purified AAT to several grams of highly purified protein. Moreover, the chronic augmentation and maintenance therapy in individuals with emphysema due to congenital AAT deficiency (current applications in the clinical setting) is also presented.
本报告旨在回顾从 20 世纪 50 年代至今用于从人血浆中纯化α1-抗胰蛋白酶(AAT)的方法。AAT 是一种糖蛋白,其主要功能是保护组织免受人类中性粒细胞弹性蛋白酶(HNE)和中性粒细胞在炎症状态下释放的其他蛋白酶的侵害。这种抑制剂在人血清中的缺乏导致了α1-抗胰蛋白酶缺乏症(AATD)的发生,这是一种严重的遗传疾病,会影响成年人的肺部,目前尚无治愈方法。AAT 在某些特殊情况下被用作 AATD 的“替代”治疗(包括静脉输注缺失的蛋白质),是一种具有重要治疗意义的分子。出于这个原因,近年来,人们对从人血浆中纯化 AAT 或通过重组方式生产 AAT 的兴趣大大增加。本文追溯了所有技术进步,这些进步使制造商能够从几微克部分纯化的 AAT 到几克高度纯化的蛋白质。此外,还介绍了由于先天性 AAT 缺乏导致的肺气肿患者的慢性增强和维持治疗(目前在临床环境中的应用)。